Nalaganje...

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy

Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GB...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Joshi, Avadhut D., Loilome, Watcharin, Siu, I-Mei, Tyler, Betty, Gallia, Gary L., Riggins, Gregory J.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2012
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3462750/
https://ncbi.nlm.nih.gov/pubmed/23056179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044372
Oznake: Označite
Brez oznak, prvi označite!